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Background: Decision-making is an essential function of everyday life. Decision-making under explicit risk requires
developing advantageous decision strategies based on fixed outcomes (e.g., probabilities of winning or losing
a bet). Decision-making and its neural substrates have been rarely studied in MS. We expected performance in
decision-making under risk to be lowered in MS patients, and negatively correlated with disease-related disability,
cognition, and ventricular width.
Methods: Three groups were included: 32 MS patients and 20 healthy controls were examined with conventional
neuropsychological tests and the Game-of-Dice Task (GDT) assessing decision-making under explicit risk. Linear 2-D
ventricular width was assessed on MS patients’ clinical MRIs and compared to a third group, 20 non-MS neurological
control patients.
Results: Compared to healthy controls, MS patients showed impaired GDT and neuropsychological performance,
depending on the MS-subtype (relapsing-remitting (RR), n = 22; secondary progressive, n = 10) and disability severity
among RR-MS patients. In MS patients, GDT performance correlated with processing speed, intercaudate ratio, and
third ventricle ratio (p’s < 0.05). Mediation analysis showed that the link between GDT performance and processing
speed was fully explained by ventricular size.
Conclusion: Decision-making under explicit risk was reduced in MS patients, but only those with more pronounced
disability. Independent of processing speed, decision-making under explicit risk correlates inversely with central
atrophy in MS.
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Multiple sclerosis (MS) is a demyelinating, inflammatory
disease of the central nervous system involving both
white matter and grey matter changes [1]. Cognitive im-
pairment, especially in processing speed and attention
[2,3], occurs in 40-60% of patients [3], and has been
linked to neurodegenerative changes [4,5]. Manual 2-D
measures of cranial ventricular width on magnetic
resonance images (MRI) are a simple way to estimate
loss of neighbouring brain parenchyma. These measures* Correspondence: efujiwara@ualberta.ca
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unless otherwise stated.have been used for many decades, have shown satisfac-
tory agreement with high-resolution 3-D MRI in MS,
and have been associated with disease severity, progres-
sion, and cognitive status in MS patients [2,6-13]. The
third ventricle width/ratio and intercaudate distance/
intercaudate ratio, often referred to as reflecting ‘central
atrophy’, seem particularly sensitive to cognitive dysfunc-
tion in MS [2,6,14,15].
Decision-making is a complex function with high
relevance to everyday life. Decision-making requires
choosing between options and using feedback from prior
choices to develop and maintain an optimal choice
strategy. The Game-of-Dice Task (GDT [16]) assesses
decision-making under explicit risk and emphasizes theral. This is an Open Access article distributed under the terms of the Creative
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mation about winning/ losing probabilities associated
with each choice. In contrast to decision-making under
explicit risk, in decision-making under ambiguity the
odds for each choice option are not made explicit. In-
stead, the goal is to implicitly learn choice-outcome
contingencies solely by feedback and trial-and-error.
The most prominent task assessing decision-making
under ambiguity is the Iowa Gambling Task (IGT [17]).
A number of studies using the IGT [17] have found im-
pairments in MS, but these were usually independent
of cognitive deficits [18-22]. Two previous MS studies
used the GDT. Farez and others (2014) [23] reported
deficits in 27 relapsing-remitting MS patients with min-
imal disability (mean Expanded Disability Status Scale
[EDSS] [24] = 1.03) and short disease duration (mean =
7.9 months). Patients’ GDT performance was related to
processing speed and visual memory performance [23].
Conversely, Cogo and others (2014) [25] found 60
relapsing-remitting MS patients with minimal disability
(mean EDSS = 1.4) but longer disease duration (mean =
40.8 months) unimpaired on the GDT. In their study,
GDT performance in MS patients was unrelated to
other cognitive functions. These findings require fur-
ther clarification.
Patients with several primary neurodegenerative disor-
ders have shown deficits on the GDT and other
decision-making tasks [26]. In MS, one decision-making
study (using the IGT) [18] tested patients with a rela-
tively long disease duration (median = 8.58 years) and
higher levels of disability (median EDSS = 2.0), i.e., indi-
viduals with probable neurodegenerative changes due to
the progression of MS. In this study, decision-making
deficits on the IGT were observed only in MS patients
with EDSS > 2. However, direct neuroanatomical sub-
strates of decision-making in MS are rare. Roca et al.
[20] tested decision-making in the IGT in 12 MS
patients in conjunction with diffusion tensor imaging
(fractional anisotropy and apparent diffusion coefficient)
along frontal lobe white matter bundles (orbito-frontal,
fronto-lateral, fronto-medial and gyrus cinguli regions).
They reported no association between the structural
integrity along any of these frontal white matter bundles
and decision-making performance in their MS patients.
A recent larger-scale study [27] with 105 MS patients
with varying levels of disability examined another
decision-making paradigm, the Cambridge Gambling
Task (CGT). The authors used the CGT in combination
with diffusion MRI (diffusion orientational complexity),
measurement of grey matter volumes, and white matter
lesion volume. The decision-making speed in the CGT
in particular was impaired in the MS group, especially in
secondary progressive MS patients (n = 26). Decision-
making speed in the MS group was correlated withcognitive functions (processing speed, memory, execu-
tive functions), and with diffusion orientational complex-
ity (grey matter pathology) in the medial prefrontal,
middle frontal gyrus, anterior cingulate and the caudate,
as well as with white matter lesion volumes. This net-
work of medial frontal-caudate regions matches well
with previous decision-making findings from primary
neurodegenerative disorders [26]. However, it should
also be noted that the CGT is a speeded task, unlike the
GDT. Muhlert et al. [27] did not report whether the
identified correlations between grey/white matter path-
ologies and decision speed were also present for process-
ing speed in general. Of note, another study using the
CGT [28] also found decision speed in the CGT corre-
lated with processing speed in MS. Thus, using the CGT
as a measure, it remains possible that slowing in pro-
cessing speed also contributes to problems with speeded
decision-making in MS and therefore may share neural
substrates.
Therefore, our goals with the current study were
to test whether the GDT as a non-speeded measure of
decision-making under explicit risk is impaired in MS,
and to evaluate whether GDT performance is linked to
increasing disability (defined here as functional impair-
ment according to the EDSS [24]) and to atrophic brain
changes. Using measures of ventricular width to
approximate brain atrophy, we included MS patients
with EDSS scores between 0 and 6.5. The following hy-
potheses were tested: We expected that GDT perform-
ance would be impaired in MS as a function of disability
and ventricular width. Because the GDT is usually corre-
lated with executive functions in non-MS populations
[16,29,30], we expected to observe a correlation between
the GDT and executive function. However, one MS
study with the GDT [23] found correlations between
decision-making and processing speed. Therefore, we
tested whether our group would also show correlations
between GDT performance and processing speed.
Finally, we tested whether potential associations between
GDT performance and ventricular width were mediated
by other cognitive functions.
Methods
This study was conducted in adherence to the Declaration
of Helsinki and with approval from the University of
Alberta Health Research Ethics Board (ethics file numbers:
Pro00007274; Pro00041844). All participants provided
written informed consent.
Participants
The MS patients (n = 32) were recruited through the
Northern Alberta Multiple Sclerosis Clinic in Edmonton.
Healthy controls (n = 20) were recruited through online
and print advertisements. Exclusion criteria for all
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logical or psychiatric condition(s), apart from MS for
the patients, b) substance abuse within the past
5 years, c) uncorrected vision/hearing problems, d)
non-fluency in English, e) current corticosteroid treatment.
Only patients with a diagnosis of relapsing-remitting (RR-)
or secondary progressive (SP-) MS (revised McDonald cri-
teria [31]) and an EDSS [24] score < 7 were included.
Due to our sampling and inclusion of a large range of
EDSS scores, the variability of disability within the RR
subtype was rather high. In order to explore potential
decision-making differences within the heterogeneous
group of RR-MS patients and to equate sample sizes, pa-
tients were further sub-divided into three groups based
on disability and subtype: (1) RR-1: RR-MS patients with
EDSS < 3.0, indicating no to minimal disability (n = 13),
(2) RR-2: RR-MS patients with EDSS ≥ 3.0, indicating
moderate disability (n = 9), and (3) SP: SP-MS patients
with EDSS ≥ 3.0 (n = 10). The rationale for further split-
ting of the RR-MS subgroup was to illustrate a gradient
of possible decision-making (and other cognitive) deficits
as a function of disability within the larger group of pa-
tients with the RR subtype. Our choice of EDSS cut-off
score was motivated such that in the EDSS, a score less
than 3 indicates at most, mild disability in one functional
system or minimal disability in two functional systems.
Scores 3 and higher include moderate disability levels,
which we intended to distinguish from minimal-mild
disability levels.
MS patients were currently taking a variety of pre-
scription medications for health conditions not part of
the exclusion criteria, including high blood pressure,
high cholesterol, heartburn and acid reflux, osteoarthritis
and bone density, asthma, and gastrointestinal/urological
concerns. Participants on the antidepressants bupropion,
selective serotonin reuptake inhibitors and selective nor-
epinephrine reuptake inhibitors were permitted. Since it
is common for MS patients (especially SP-MS patients)
to be prescribed psychotropic drugs for symptom man-
agement (i.e. insomnia, neuropathic pain), these patients
were not excluded from the study, even though these
medications have the potential to impact cognition.
Thus, some MS patients were on low doses of benzodi-
azepines and anticonvulsants. Current self-reported
medications were obtained from all 32 MS patients. In
total, 9 RR-MS patients (28.13%, 5 RR-1, 4 RR-2) were
currently prescribed a disease-modifying drug (i.e., inter-
feron beta or glatiramer acetate), with no patients pre-
scribed both interferon beta and glatiramer acetate
simultaneously. No SP-MS patients were prescribed
disease-modifying drugs. Twenty-one patients (65.63%;
8 RR-1, 6 RR-2, 7 SP) were taking at least one prescrip-
tion medication for MS and/or neurological concerns.
Ten patients (31.25%; 4 RR-1, 1 RR-2, 5 SP) were onmore than one medication. In total, two patients (6.25%)
were on a medication for neuropathic pain (1 RR-2, 1 SP),
five patients (15.63%) were prescribed a medication for
sleep and/or anxiety (2 RR-1, 3 SP), twelve patients
(34.38%) were prescribed antidepressants (6 RR-1, 1 RR-2,
4 SP), and nine patients (28.13%) were on anti-spasticity or
muscle relaxation medications (2 RR-1, 2 RR-2, 5 SP).
Table 1 shows healthy controls were comparable to
MS patients in gender distribution, age, education, and
estimated premorbid IQ [32]. Disease duration and age
at onset of MS were statistically not different among pa-
tient subgroups, although it should be noted that the
RR-2 group had on average a 6–7 years shorter disease
duration than both the RR-1 and the SP subgroup. This
pattern reflects that the RR-1 subgroup would have had
relatively little functional impairment over long periods
of time, sometimes called ‘benign MS’. The exact criteria
and existence of such a subtype are widely debated,
therefore we retain the more neutral RR-1 label here
[33-36]. In agreement with an interpretation of a more
benign disease course in the RR-1 group, the Multiple
Sclerosis Severity Score (MSSS; [37]) indicated a more
aggressive disease course in the RR-2 and SP groups
than in RR-1.
In order to provide a reference for the ventricular
width measures we applied to retrospectively collected
cranial MRIs of the MS patients (see section MRI scans),
we included a third group. This group were 20 patients
who had undergone cranial MRI scanning for the fol-
lowing reasons: Syncope: n = 1, cranial nerve palsy: n = 1,
transverse myelitis: n = 2, encephalitis: n = 2, systemic
lupus erythematosus: n = 2, optic neuritis: n = 1, lacunar
stroke: n = 1, systemic lupus erythematosus cerebritis:
n = 1, epilepsy: n = 1, seizure: n = 3, brainstem stroke:
n = 2, spinal cord stroke: n = 1, cerebelitis, transient
ischemic attack: n = 1, Sneddon’s Syndrome: n = 1).
Neuropsychological tests
The neuropsychological test battery included conven-
tional tests of processing speed (Symbol-Digit Modality
Test, Paced Auditory Serial Addition Test – 3-second
version, 9-hole Pegboard, Forward Digit Span), verbal
memory (Verbal Selective Reminding Task, SRT), and
executive functions (intrusions in the SRT, Wisconsin
Card Sorting Test, Phonemic Fluency, Tower of Hanoi,
Backward Digit Span). Acknowledging that neuro-
psychological measures, especially executive function
tests, are not process-pure and are combinable in multiple
ways, we attempted to minimize type-I error by reducing
the number of comparisons. Therefore, we summarized
the individual test scores into three composite z-scores
based on the performance of the healthy controls in our
study: processing speed, memory, and executive functions.
A global cognitive function z-score was derived by
Table 1 Background variables
HCs (n = 20) MS (n = 32) Test RR-1 (n = 13) RR-2 (n = 9) SP (n = 10) Test
Female, n (%) 12 (60%) 24 (75%) χ2 = 1.3 11 (84.6%) 6 (66.7%) 7 (70%) χ2 = 2.28
p = 0.47 p = 0.60
Age, years 48.2 (11.0) 50.81 (9.5) t = 0.9 52.0 (9.8) 46.8 (10.7) 52.9 (7.5) F = 0.96
p = 0.37 p = 0.55
Education, years 14.7 (2.1) 13.6 (1.7) t = −2.0 14.2 (2.1) 13.2 (1.7) 13.4 (0.9) F = 1.88
p = 0.051 p = 0.15
Premorbid IQ 110.2 (11.7) 105.2 (12.2) t = −1.48 110.9 (10.3) 101.2 (15.3) 101.4 (9.0) F = 2.53
p = 0.15 p = 0.07
MS-onset age, years – 34.4 (9.7) – 34.1 (9.2) 35.1 (9.7) 34.3 (11.2) F = 0.03
p = 0.98
Disease duration, years – 15.9 (10.3) – 17.2 (12.8) 11.3 (7.5) 18.4 (8.4) F = 1.32
p = 0.28
EDSS score (medians, ranges) – 3 (0–6.5) – 2 (0–2.5) 3.5 (3–6.5) 6 (3–6.5) –
MSSS – 3.9 (2.8) – 1.7 (2.0) a 5.5 (2.5) b 5.3 (1.8) b F = 12.0
p < 0.001
Disease-modifying therapy 1 – 9 (28.1%) – 5 (38.5%) 4 (44.4%) 0 (0.0%) –
Abbreviations: EDSS Expanded Disability Status Scale; HCs Healthy controls; MSSS Multiple Sclerosis Severity Score; RR-1 Relapsing-remitting MS patients with EDSS
scores 0–2.5; RR-2 Relapsing-remitting MS patients with EDSS scores ≥ 3; SP Secondary progressive MS patients.
1 Interferon beta 1a or 1b or glatiramer acetate.
ab Different superscripts indicate significant between-group differences in post-hoc t-tests, Bonferroni-corrected.
Data are means (standard deviations) unless stated otherwise.
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chosocial and symptom questionnaires were adminis-
tered to MS patients only (Hospital Anxiety and
Depression Scale, Fatigue Assessment Inventory, Dysexe-
cutive Questionnaire, London Handicap Scale). Test refer-
ences, assignment of individual tests to the composite





Processing speed composite score 0.00 (0.76) −0.81 (0.81)
Memory composite score 0.00 (0.93) −1.54 (1.16)
Executive functions composite score 0.00 (0.59) −0.63 (0.69)
Global cognitive functions composite score 0.00 (0.63) −0.93 (0.63)
GDT – net-score (raw score) 12.5 (7.6) 6.8 (10.9)
GDT – strategy shifts (raw score;
medians/ranges)
1 (0–10) 3.5 (0–12)
Abbreviations: HCs: Healthy controls; GDT Game-of-Dice Task; RR-1 Relapsing-remitti
Relapsing-remitting MS-patients with EDSS scores ≥ 3; SP Secondary progressive MS
*Significant difference to healthy controls (post-hoc Dunnett t-test or Bonferroni-co
Data are means (standard deviations) or medians (ranges).Additional file 1 lists references and norm-based results of
the MS patients in the questionnaires.
Game-of-Dice Task (GDT)
The computerized GDT assessed decision-making under
explicit risk, and has been described previously in detail








t = 3.58 −0.45 (0.60) −1.04* (0.61) −1.07* (1.07) F = 6.13
p = 0.001 p = 0.001
t = 5.02 −1.19* (1.23) −1.57* (1.36) −1.97* (0.76) F = 9.59
p < 0.001 p < 0.001
t = 3.41 −0.53 (0.85) −0.85* (0.71) −0.58 (0.39) F = 4.30
p = 0.001 p = 0.009
t = 5.12 −0.61* (0.65) −1.11* (0.71) −1.18* (0.35) F = 10.54
p < 0.001 p < 0.001
t = 2.1 13.69 (5.82) 0.22* (11.77) 3.80* (10.73) F = 4.87
p = 0.046 p = 0.01
U = 1.6 2 (0–8) 4 (0–10) 5.5* (1–12) χ2 = 41.0
p = 0.069 p = 0.009
ng MS-patients with EDSS (Expanded Disability Status Scale) scores 0–2.5; RR-2
-patients.
rrected U-test).
Table 3 Performance in individual neuropsychological tests
Neuropsychological
domain/test
HCs (n = 20) All MS patients
(n = 32)
Test RR-1 (n = 13) RR-2 (n = 9) SP (n = 10) Test
Processing speed composite score
SDMT [61] 52.30 (12.34) 44.29 (9.63) t = 2.60 48.31 (8.87) 40.00* (9.24) 42.50 (9.71) F = 3.47
p = 0.01 p = 0.02
PASAT [52,53] 48.80 (10.44) 43.44 (11.06) t = 1.74 48.54 (5.38) 34.67* (12.49) 44.70 (11.31) F = 4.65
p = 0.089 p = 0.006
Forward Digit Span [62] 11.10 (1.92) 9.94 (1.83) t = 2.19 10.38 (1.98) 10.00 (1.50) 9.30 (1.89) F = 2.24
p = 0.033 p = 0.10
Pegboard (Dominant/
Non-dominant hand) [63]
27.40 (4.56) 33.95 (9.87) t = 3.24 32.25 (9.29) 32.80 (5.48) 37.19* (13.30) F = 3.35
p = 0.002 p = 0.03
Memory composite score
SRT Immediate [64,65] 53.65 (6.85) 39.09 (10.96) t = 5.32 42.08* (11.62) 39.11* (12.43) 35.20* (8.15) F = 14.31
p < 0.001 p < 0.001
SRT CLTR [64,65] 36.85 (13.14) 18.00 (13.24) t = 5.01 21.00* (14.50) 19.11 (16.44) 13.10* (6.49) F = 13.85
p < 0.001 p < 0.001
SRT Delayed [64,65] 8.10 (2.43) 5.53 (2.55) t = 3.60 6.46 (2.50) 5.11* (2.89) 4.70* (2.11) F = 5.67
p = 0.001 p = 0.005
Executive functions composite score
Tower of Hanoi, Time [60,66] 317.25 (139.78) 384.81 (132.47) t = 1.74 417.67 (118.32) 390.67 (179.25) 340.11(95.56) F = 1.61
p = 0.088 p = 0.20
WCST 64-cards, correct sorts [67] 50.65 (3.88) 47.13 (7.71) t = 2.18 48.92 (8.35) 44.11 (8.42) 47.50 (5.89) F = 2.07
p = 0.034 p = 0.14
WCST 64-cards, perseverative
errors [67]
6.45 (2.11) 8.44 (5.65) t = 1.46 7.85 (5.06) 8.44 (4.10) 6.90 (2.92) F = 0.83
p = 0.15 p = 0.48
Backward Digit Span [62] 7.65 (1.79) 6.22 (2.01) t = 2.60 6.77 (1.79) 5.78 (2.82) 5.90* (1.37) F = 3.14
p = 0.012 p = 0.046
FAS Total Correct [68] 46.50 (10.59) 36.69 (9.10) t = 3.55 38.15 (10.37) 36.33* (9.14) 35.10* (7.84) F = 4.28
p = 0.001 p = 0.009
SRT Intrusions [64,65] Md. 0.00 (Rg. 0–12) Md. 1.00 (Rg. 0–6) U = 230 p = 0.09 Md. 1.00 (Rg. 0–3) Md. 0.00 (Rg. 0–4) Md. 1 (Rg. 0–6) χ2 = 5.26
p = 1.54
Abbreviations: CLTR Continuous long-term retrieval; FAS Phonemic (letter) Fluency; HCs Healthy controls; Md median; PASAT Paced Auditory Serial Addition Test;
Rg Range; RR-1 Relapsing-remitting MS patients with EDSS (Expanded Disability Status Scale) scores 0–2.5; RR-2 Relapsing-remitting MS patients with EDSS scores≥ 3;
SP Secondary progressive MS patients; SDMT Symbol Digit Modalities Test; SRT Selective Reminding Test; WCST Wisconsin Card Sorting Test, 64-card version.
*Significant difference to healthy controls (post-hoc Dunnett t-test or Bonferroni-corrected U-test).
Data are means (standard deviations) or medians (ranges).
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outcome of a single dice throw. Betting choices include
single, 2-, 3- and 4-number combination bets ranging in
winning/losing probabilities and possible pay-outs (i.e.,
1-number bets: 1:6 chance of winning and 5:6 chance of
losing $1000; 4-number bets: 4:6 chance of winning and
2:6 chance of losing $100). Choices with a less than 50%
chance of winning (1- and 2-number bets) are termed
‘high-risk’. Choices with at least 50% winning probability
(3- and 4-number bets) are termed ‘low-risk’. Choice
options and possible pay-outs are explicitly explained
and are displayed throughout the task. Hence, the
GDT assesses decision-making under explicit risk.The main outcome measure is the GDT net-score
(low-risk minus high-risk choices; minimum = −18,
maximum = +18, high scores indicate less risky
choices). Another outcome measure is ‘strategy shifts’,
which is the sum of alternations between high-risk
and low-risk GDT choices (maximum = 17). Strategy
shifts reflect errors in using feedback to develop and
maintain a coherent choice strategy across the entire
length of the GDT [30].
MRI scans
Retrospective clinical MRI scans were available from the
medical charts of 31 of the 32 MS patients and from the
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MRIs were deemed unremarkable by their treating phy-
sicians. Given the nature of this recruitment strategy,
scans were performed in different centres with a variety
of protocols. Details on each participants’ scan protocol
for the T2-weighted MRIs used for the ventricular mea-
sures are provided in Additional file 2. All scans were
acquired on 1.5 Tesla MR scanners. In all but 4 cases
(2 MS, 2 non-MS), a 5 mm slice thickness and 6.5 mm
inter-slice gap was used. For the MS patients, average
time between MRI and cognitive testing was 9.52 ±
12.88 months. The main purpose for including ventricu-
lar measures from the non-MS control patients was to
compare ventricular widths on similar retrospectively
sampled clinical MR scans against those of the MS pa-
tients. In past studies, linear ventricular width measures,
especially third ventricle width (TVW) and intercaudate
distance/ intercaudate ratio (ICD/ICR) have differenti-
ated well between MS patients and healthy controls
[2,12,38,39]. Thus, our approach to include a non-MS
patient group as a reference can be considered con-
servative. In the MS patients only, we correlated
ventricular width measures with EDSS and disease
duration to test whether these measures reflected MS
severity/progression in our sample, similar to approaches
in past studies [39-41].
Ventricular width measures
Linear measurements of ventricular width were performed
on the MR images using a digital ruler in ClearCanvas
Workstation 2.0. (https://www.clearcanvas.ca). Measures
were made on the most caudal axial T2-weighted slice
where the frontal horns appeared to reach maximal width
[9] (see Additional file 3 for an illustrated example). Mea-
sures included: 1) Frontal Horn Width (FHW): Maximal
distance between the lateral borders of the frontal horns
of the lateral ventricles; 2) Intercaudate Distance (ICD):
Minimum distance between the medial borders of the
head of the caudate nuclei; 3) Third Ventricle Width
(TVW): Maximum distance between the lateral borders
of the middle of the third ventricle where the ventricles’
borders are most parallel; 4) Frontal Horn Ratio (FHR):
FHW divided by the Transverse Width (TW): Minimum
distance separating the inner tables of the skull at the
level of the caudate nuclei; 5) Intercaudate Ratio (ICR):
ICD divided by the TW; 6) Third Ventricle Ratio (TVR):
ICD divided by the TW. Thus, we recorded three abso-
lute measures (FHW, ICD, TVW) and three ratios (FHR,
ICR, TVR) correcting the three ventricular width
measures for brain width. The three ventricular
width measures as well as the transverse width were
recorded three times (A.D.R.) yielding excellent intra-
rater reliability (intra-class coefficients: FHW = 0.992;
ICD = 0.995; TVW= 0.997; TW= 0.989). An average ofthese three measures was used in the analyses and to
derive the ratio measures. A second rater repeated all mea-
sures, yielding high inter-rater reliability (FHW= 0.876;
ICD = 0.983; TVW= 0.968; TW= 0.987).
The use of different imaging facilities, scanner
models, and imaging protocols in a retrospective sam-
pling approach such as here could conceivably lead to
systematic biases. Seven different scan sites were in-
cluded, with 38 of the 51 scans (24 MS patients,14 non-
MS control patients) from site 1. Sites 2–7 had between
1 and 3 scans per site with a total of 13 scans from sites
2–7 (7 MS patients, 5 non-MS control patients). Further-
more, scans were from six different MR scanners. More
than half of the scans (n = 29) were acquired with a
Siemens Avanto scanner model (21 MS patients, 8 non-
MS control patients), with substantially fewer scans from
the additional five scanners (details see Additional file 2).
The small total number of scans and imbalanced fre-
quencies of individual scans per site/scanner precluded a
direct comparison of the ventricular width measures be-
tween each individual site/scanner. In order to allow
some comparison and quality control nevertheless, we
dichotomised ‘scan site’ and ‘scanner model’, and tested
differences in the ventricular width measures between
sites (site 1 versus sites 2–7), and between scanners
(Siemens Avanto vs. other scanner models). Briefly,
none of the comparisons yielded significant differ-
ences in any of the six ventricular width measures
between scan sites or scanner models (see Additional
file 4 for details). Thus, despite the limitations of this
retrospective MR sampling method, we did not observe
systematic biases in the ventricular measures across scan
sites or scanner models.
Statistical analyses
Statistical standard procedures were carried out with
SPSS 22.0 for Windows (IBM SPSS Statistics). Data were
tested for normality with Kolmogorov-Smirnoff test.
Non-normality was observed in the following variables:
Intrusions in the Symbol Digit Modalities Test, third
ventricle width, third ventricle ratio, GDT strategy shifts.
The EDSS score was marginally normal (p = 0.052).
Comparisons between two groups (MS patients versus
healthy controls) were carried out with t-tests or with
non-parametric U-tests, if indicated. Patient subgroups
(RR-1, RR-2, and SP) were contrasted to controls by ana-
lysis of variance and post-hoc Dunnett t-tests, correcting
for multiple comparisons. As non-parametric equivalent,
the Kruskall Wallis test and post-hoc Bonferroni-
corrected U-tests against controls were used, if indi-
cated. Moderated regression analyses were carried out to
control for demographic differences between patient
subgroups potentially influencing decision-making
performance. Simple correlations between variables
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tions, respectively. Partial correlations were Pearson
correlations, with preceding log-transformation of non-
normal variables. To limit the total number of correla-
tions, only ventricular ratios (not absolute ventricular
width measures) were correlated with disease parame-
ters and cognitive variables. However, even despite
these restrictions and the use of cognitive composite
scores instead of individual tests, the total number of
correlations carried out here could inflate type-1 error.
To retain some sensitivity in light of the small sample
size, we report both, the uncorrected correlation re-
sults and those adjusted by false-discovery rate ac-
counting for the number of correlations [42]. A
structural equation model to test mediation effects was
carried out using the MPlus modelling framework [43].
Before testing the model, the fits of the latent
dimensions underlying ventricular widening were tested
using confirmatory factor analysis (CFA), also in MPlus.
For both, mediation analysis and CFA, maximum likeli-
hood parameter estimation was applied. Standard cri-
teria were used for the evaluation of model fits [44,45].
These included: Standardized root mean square re-
sidual (SRMR; values below .08 indicate a good fit with
the data), comparative fit indices (Bentler’s comparative
fit index [CFI] and Tucker-Lewis index [TLI]; values
above .90 indicate a good fit, values above .95 an excel-
lent fit), and root mean square error of approximation
(RMSEA; “test of close fit”; a value below .08 with a sig-
nificance value below .05 indicates an acceptable fit).
Results
Neuropsychological performance and psychosocial
variables
Results on the individual tests contained within the cog-
nitive composite scores are shown in Table 3.
MS patients showed significantly lower performance
than healthy controls on the composite scores for pro-
cessing speed, memory, and executive functions, and con-
sequently also in global cognitive functioning (Table 2).
Comparing individual MS patient subgroups against
healthy controls, the RR-1 group underperformed in
memory and global cognitive functions, the RR-2 group
scored below healthy controls in all domains, and the SP
group was impaired in all domains except executive
functions. Compared to published cut-off scores, MS pa-
tients reported severe fatigue, but no elevated levels of
anxiety or depression, and only mild dysexecutive symp-
toms (see Additional file 1).
Game-of-Dice Task (GDT)
Among all MS patients, the mean GDT net-score was
significantly lower than that of the healthy controls
(Table 2; Figure 1(a)).However, comparing the different MS subgroups with
healthy controls showed that GDT net-scores were sig-
nificantly reduced only in the RR-2 and SP groups. This
finding was echoed by negative correlations between
GDT net-score and EDSS (r[27] = −0.59, p < 0.001;
Spearman rho[27] = −0.66, p < 0.001) (Figure 1 (b)), as
well as GDT net-score and MSSS (r[27] = −0.42, p = 0.016).
Individual MS subgroups also differed from healthy con-
trols in the number of GDT strategy shifts, but only the
SP-MS group demonstrated significantly increased shifting
(Table 2). Thus, overall, decision-making in the GDT was
reduced only in the RR-2 and SP groups.
Of note, controlling for the marginally lower education
and premorbid IQ in the RR-2 and SP subgroups (see
Table 1), did not change these results. In detail, we con-
ducted three moderated multiple regression analyses
[46] predicting GDT net-score by years of education and
premorbid IQ (step 1), subgroup membership (step 2:
membership in the subgroups RR-1, RR-2, or SP were
dummy-coded with healthy controls as a reference
group) and their 2-way interactions (step 3). Years of
education and premorbid IQ by themselves did not
predict GDT net-score well (R2 = 0.007, F [2,47] = 0.17,
p = 0.85). Including subgroup (step 2) rendered a signifi-
cant model (R2 = 0.34; Fchange [3,45] = 7.70, p < 0.001;
F[5,45] = 4.72, p = 0.001), but including the interaction
terms in step 3 (R2 = 0.46, F[11,37] = 3.09, p = 0.004) did
not substantially increase the prediction of GDT vari-
ance over step 2 (Fchange [6,37] = 1.49, p = 0.21). The re-
gression weights in step 2 showed that RR-2 subgroup
membership (b = −14.85, standard error (SE)b = 3.76,
β = −0.57, t = −3.95, p < 0.001) and SP subgroup member-
ship (b = −11.16, SEb = 3.62, β = −0.44, t = −3.09, p = 0.003)
both predicted lower GDT net-scores compared to con-
trols, whereas membership in the RR-1 subgroup did not
(b = 0.97, SEb = 3.08, β = 0.04, t = −0.32, p = 0.75). Thus, the
GDT net-score reductions in the RR-2 and SP-subgroups
were not substantially influenced by demographic charac-
teristics of these patients.
Ventricular width
Ventricular width measures have been applied to MS
in the past to approximate atrophic brain changes
[2,6,7,9,10,12,13]. These indices have been correlated
with MS disease progression [40,48] as well as with
neuropsychological impairments [2,6,7]. Compared to
the 20 gender- and age-matched non-MS control pa-
tients, MS patients exhibited significantly larger ICD/
ICR and TVW/TVR (Table 4). The ICR measure further
differentiated patient subgroups (F[3,46] = 3.67, p =
0.019), with larger ICR in the RR-2 (p = 0.046) and SP
groups (p = 0.019) compared to the non-MS control pa-
tients (post-hoc Dunnett-t tests). Of note, the TVW
measured 2.3 mm (median) or 3.3 mm (mean) in our
Figure 1 GDT performance in MS patients and healthy controls. (a) Mean GDT net-score (low-risk minues high-risk choices) in healthy controls
compared to all MS patients and compared to MS patient subgroups. (b) Spearman rank-correlation between MS patients’ EDSS score and GDT
net-score. EDSS: Expanded Disability Status Scale; GDT: Game-of-Dice Task; RR-1: Relapsing-remitting MS patients with EDSS scores < 3; RR-2:
Relapsing-remitting MS patients with EDSS scores≥ 3; SP: Secondary progressive MS patients. Error bars are standard errors of the mean.
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MS cohorts ranging between 3.0 mm [11], 3.12 mm [9],
3.58 (RR-MS), and 5.04 (SP-MS) [2]. The FHW
(32.26 mm) and ICD (12.2 mm) were likewise similar to
previously reported cohorts (FHW: 33.33 mm, ICD:
12.12 [9]) of MS patients. Controlling for age, gender,
scan site, and scanner model, EDSS was positively corre-
lated with TVR (Table 5).
Associations between GDT, cognitive performance and
brain atrophy
Correlations were not performed within MS patient sub-
groups due to the small subgroup sample sizes. Neither
GDT net-score nor strategy shifts were significantly cor-
related with cognitive performance in healthy controls,
likely due to ceiling/floor effects. In the MS patients, the
GDT net-score was positively correlated with the pro-
cessing speed composite score (r[27] = 0.41, p = 0.019;
although not significant after False-Discovery Rate cor-
rection [42]). The GDT net-score was not correlatedwith any of the other cognitive composite scores (all
p’s > 0.1). Within the processing speed composite, all in-
dividual tests correlated with the GDT net-score in the
expected direction; the SDMT showed the strongest in-
dividual correlation (r[27] = 0.37, p = 0.043, not signifi-
cant after correction [42]). Even though the composite
score of executive functions did not correlate with GDT
net-score, we had strong apriori expectations to observe
such relationships based on prior studies [16,29,30].
Thus, we also examined relationships between the GDT
net-score and individual executive function tests. We
observed, in MS patients only, that the number of
WCST correct sorts was correlated with the GDT net-
score (r[27] = 0.38, p = 0.032, not significant after correc-
tion [42]). None of the self-report psychosocial or symp-
tom questionnaires correlated with the GDT net-score
in MS patients. Controlling for age, gender, scan site,
scanner model, and time between MR scan and test
date, the ventricular ratio measures ICR and TVR were
negatively correlated with MS patients’ GDT net-score







Female, n (%) 12 (60.00%) 23 (74.19%) χ2 = 1.14
p = 0.29
Age, years 47.8 (12.08) 50.5 (9.43) t = 0.88
p = 0.38
FHW, cm 3.18 (0.38) 3.26 (0.28) t = 0.85
p = 0.40
ICD, cm 1.04 (0.24) 1.22 (0.27) t = 2.48
p = 0.02
TVW, cm 0.17 (0.11 - 0.7) a 0.23 (0.1 - 1.0) a U = 190
p = 0.02
FHR, cm 0.28 (0.02) 0.29 (0.03) t = 1.23
p = 0.22
ICR, cm 0.09 (0.02) 0.11 (0.02) t = 2.83
p = 0.007
TVR, cm 0.02 (0.01 - 0.08) a 0.01 (0.01 - 0.06) a U = 188
p = 0.02
Abbreviations: FHW Frontal horn width; ICD Intercaudate distance; TVW Third
ventricle width; FHR Frontal horn ratio; ICR Intercaudate ratio; TVR Third
ventricle ratio.
a Medians (ranges).
Data are means (standard deviations) or medians (ranges).
Table 5 Partial correlations between ventricular ratio
measures, disease parameters and cognition in MS
patients a
FHR ICR TVR (log)
Disease duration 0.27 0.31 0.32
p = 0.17 p = 0.11 p = 0.11
EDSS 0.13 0.34 0.38
p = 0.52 p = 0.09 p = 0.049
Processing speed −0.15 −0.57 −0.53
p = 0.46 p = 0.002 b p = 0.005 b
Memory −0.01 0.003 −0.12
p = 0.98 p = 0.99 p = 0.57
Executive functions 0.13 −0.01 0.04
p = 0.52 p = 0.97 p = 0.83
Global cognitive function 0.02 −0.21 −0.23
p = 0.92 p = 0.30 p = 0.26
GDT net-score 0.03 −0.42 −0.52
p = 0.88 p = 0.03 p = 0.007 b
GDT strategy shifts (log) −0.34 −0.02 0.01
p = 0.09 p = 0.93 p = 0.98
Abbreviations: EDSS Expanded Disability Status Scale; FHR Frontal horn
ratio (cm); GDT Game-of-Dice Task; ICR Intercaudate ratio (cm); TVR Third
ventricle ratio (cm).
a Partial correlations with disease duration and EDSS controlled for age,
gender, scan site, and scanner model (df = 25). Partial correlations with
cognitive composite scores and GDT-scores additionally controlled for time be-
tween MR scan and test date (df = 24).
b p < 0.05, corrected by False-Discovery Rate [42].
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width was unrelated to the other composite scores and
to GDT strategy shifts.
To recapitulate, EDSS-based disability was only mar-
ginally related to the TVR (Table 5), but differentiated
MS-patients well on all cognitive composite scores, the
GDT net-score and the GDT stategy shift score (Table 2).
The ventricular ratios ICR and TVR in turn were more
selectively related to the processing speed composite and
to the GDT net-score (Table 5). To clarify whether the
GDT net-score was fully or partly mediated by process-
ing speed and to rule out a possible redundancy between
the GDT and tests of processing speed, we conducted a
mediation model on the GDT net-score using MPlus
[43]. Predictors were ICR and the log-transformed TVR
(modelled together as latent variable “central atrophy”);
the processing speed composite score was used as a me-
diator. We did not include any additional covariates or
mediators in this model (i.e., age, gender, scan site, scan-
ner model, or delay between test date and scan date).
These variables did not show significant bivariate
correlations with GDT net-score and with ICR/TVR;
therefore they did not fulfil the necessary criteria for medi-
ation [43]. Standard model fits indicated a good represen-
tation of our data by this model (see Figure 2).
In total, 38% of the variance in MS patients’ GDT net-
score was explained by central atrophy and processingspeed. However, whereas the direct effect of central atro-
phy on GDT net-score was highly significant (p = 0.008),
the indirect effect via processing speed was decidedly
not significant (p = 0.99). Thus, GDT performance was
not mediated by processing speed. Instead, central atro-
phy independently predicted both slowed processing
speed as well as disadvantageous decisions in the GDT
in the MS patients.
Discussion
Our goals were to test whether the GDT as a non-
speeded measure of decision-making under explicit risk
is impaired in MS, and to evaluate whether GDT per-
formance is linked to increasing disability and to ven-
tricular width. We further tested whether we could
observe correlations between GDT performance, ex-
ecutive functions, and processing speed. Finally, we
assessed whether potential associations between GDT
performance and ventricular width were mediated by
other cognitive functions.
We observed reductions in the GDT in MS patients,
but limited to patients with more severe disability. Pa-
tients’ decision-making performance was correlated with
enlarged intercaudate ratio and third ventricle ratio. We
Figure 2 Mediation model of central atrophy (latent variable) predicting processing speed (observed) and GDT net-score (observed) [28]. Model
fits were adequate according to RMSEA (root mean square approximation), CFI (Bentler's Comparative Fit Index), TLI (Tucker-Lewis Index), SRMR
(Standardized Root Mean Square Residual), and χ2. Coefficients (standard errors) are standardised. GDT: Game-of-Dice Task; ICR: Intercaudate ratio;
TVR: Third ventricle ratio. * p < 0.05; ** p < 0.01.
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and GDT performance in the MS-patients, but no
strong links to executive functions. The relationship be-
tween processing speed and GDT performance was fully
explained by intercaudate/ third ventricle ratios, pointing
to a role of central atrophy in decision-making regard-
less of processing speed deficits in MS.
In addition to white matter lesions, demyelination
and/or neuronal loss in grey matter has been highly pre-
dictive of cognitive deficits in MS [2,5-7]. Simple linear
ventricular width measures from routine clinical MRI
scans offer reasonably stable estimates of whole-brain or
regional atrophy [2,8,9,12,13,40,49]. For example, Turner
et al. (2001) [12] reported a significant correlation of
r = 0.81 between the third ventricle width assessed on
2-D MRI and the 3-D volume of the third ventricle
in 20 relapsing-remitting (RR) and 20 secondary progres-
sive (SP) MS patients. Sharma et al. [13] reported simi-
larly high correlations between whole-brain/parenchymal
fraction assessed via 3-D MRIs and linear ventricular
width measures (bicaudate ratio: r = −0.74, third ven-
tricle: r = −0.81) in 52 MS patients (43 RR-MS and 9 SP
MS). Bermel et al. [8] found 3-D brain/parenchymal frac-
tion inversely correlated with third ventricular width (r =
−0.79, p < 0.001) in 78 MS patients. Significant correla-
tions were also reported by Butzkueven et al. [9]: Inter-
caudate ratio (r = −0.45) and third ventricular ratio (r =
−0.65) were inversely correlated with volumetric brain/
parenchymal fraction in 35 MS patients. Indeed, Cifelli
et al. [49] reported a negative correlation of r = −0.59 be-
tween 2-D MRI-based third ventricle width and thalamicneuron count in a post-mortem study of 14 secondary
progressive MS patients. Thus, 2-D ventricular width
measures, especially third ventricle width, have shown
moderate to high correlations with whole-brain or regional
atrophy in MS. Correlations between linear ventricular
width measures and clinical variables in MS (disability,
disease progression, MS subtype) as well as cognitive
functions have been well-studied [2,6,7,10,13-15,40,41].
The TVW/TVR and ICR have been particularly predictive
of MS-related cognitive impairment [2,7,10], echoing the
present findings. Of note, the present study does not
claim to examine the absolute extent of ventricular
enlargement in the MS sample, which is likely under-
estimated due to our use of neurological controls for
validation of the measures.
Compared to the RR-1 and the SP patient subgroups,
the RR-2 subgroup was most impaired in the GDT and
across all of the composite scores. Among the possible
reasons for this unexpected finding may be characteris-
tics of the subgroups: Some of the RR-1 patients may
have had a ‘benign’ subtype of MS. In turn, the SP pa-
tients could be considered as being in a stable state of
disease progression without experiencing any remissions.
In this regard, a previous decision-making under ambi-
guity study [21] found that RRMS patients without re-
cent (>15 months) MS relapses had higher executive
function scores than patients with recent relapses. Al-
though we did not measure relapses in this study, it is
possible that the RR-2 patients were at a stage of transi-
tioning into an SP subtype. The conversion from an RR
to an SP subtype is marked by an increase in cognitive
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eration of the cerebral grey matter [51]. One could
speculate then that the apparent cognitive dysfunctions
as well as decision-making impairment in the RR-2
group may reflect a currently less stable disease state
than in both RR-1 and SP patients here. However, in
light of the very small group sizes, this remains
speculative.
To our knowledge, decision-making under explicit risk
in MS-patients has been assessed in four studies, two also
using the GDT [23,25] and two using the Cambridge
Gambling Task (CGT [27,28]). The CGT is a timed task
and, although MS patients were not substantially im-
paired in the CGT, their decision deliberation times were
slowed in Simioni et al. [28]. Perhaps not surprisingly,
patients’ slowed CGT decisions were related to process-
ing speed (in the Paced Auditory Serial Addition Task
[52,53]). In Muhlert et al. [27], decision deliberation time
was also the most sensitive CGT metric to differentiate
MS patients from healthy controls, although here the
correlations were more general involving processing
speed, memory, and executive functions. The MS pa-
tients in Farez et al. [23] were impaired in the untimed
GDT, again correlated with processing speed. These find-
ings together with the current GDT findings suggest that
slowed processing speed may represent a domain-general
deficit in MS, underlying deficits in untimed tasks [54],
and extending to decision-making in the GDT.
However, GDT performance has not been related to
processing speed in non-MS samples [16,29], and since
the GDT is untimed, it seems unlikely that slowed pro-
cessing speed could directly affect GDT performance.
Furthermore, comparing the three MS cohorts studied
with the GDT so far (our study, [23], [25]), it appears
that potential MS-related GDT-deficits should be
viewed in light of the disease course and cognitive defi-
cits. Intact GDT performance in our RR-1 patients and
in the RR-MS patients of Cogo et al. [25] contrasted
GDT impairment reported by Farez et al. [23]. Cogo et
al’s patients were cognitively intact, our RR-1 group
was only impaired in verbal memory, and Farez et al’s
sample was impaired in processing speed, visual mem-
ory, and verbal fluency. The other core variable differ-
entiating the three samples was disease duration,
ranging from 7.9 months in Farez et al., to 3.3 years in
Cogo et al., and reaching more than 17 years in our
RR-1 group. Although speculative, it is possible that
Farez et al. [23] included individuals with a more ag-
gressive disease course, relative to our RR-1 group and
to Cogo et al. [25]’s patients. Farez et al.’s finding of a
link between GDT performance and processing speed
(as well as visual memory) could then perhaps be
understood as accompanying a more aggressive disease
course.Our and other findings [18,27] suggest that similar to
other cognitive functions, decision-making abilities in
MS can deteriorate with disease progression or severity
of functional disability. EDSS-based disability was more
generally related to all cognitive composite scores here,
including also GDT performance (Table 2). The ven-
tricular measures (ICR, TVR) were more selectively cor-
related only with the processing speed composite score
and with the GDT net-score, and only the TVR was
related to EDSS (Table 5). Relationships between brain
atrophy, physical disability and cognition in MS are
complex. EDSS-based disability covaries with cognitive
status, and in turn cognitive functions can predict also
physical health-related quality of life [55,56]. In direct
comparison, MS-related brain changes, especially grey
matter loss, have been more predictive of cognitive im-
pairment in MS than physical disability measured by the
EDSS [57,58]. However, the ventricular width measures
here are a rather coarse estimate of brain atrophic
changes. It therefore remains possible that more direct
assessment of actual loss of brain tissue/volume would
have been more sensitive to the additional cognitive defi-
cits we found covarying with the EDSS score here.
Our mediation results speak more directly to the possi-
bility that decision-making abilities in MS can deteriorate
with disease progression. As such, MS progression indi-
cated by central atrophy, independently predicted both
processing speed deficits and decision-making deficits in
our sample. In addition, the relationship between the two
cognitive functions was eliminated when accounting for at-
rophy. The question remains then what aspects of the
GDT, besides slowing in processing speed, may underlie
the link with the central atrophy measures we observed
here. We found some evidence for a correlation between
specific aspects of executive functions (correct sorts in the
Wisconsin Card Sorting Test) and decision-making. Sev-
eral studies have demonstrated that the GDT net-score
correlates with performance in card sorting tests
[16,29,30,59]. These tasks assess the set-shifting compo-
nent of executive functions [60]. If set-shifting is a crucial
executive function involved in the GDT, using a composite
executive function score might have eclipsed its overall re-
lationship with GDT. Furthermore, the GDT also involves
reward-processing from choice feedback. We did not test
MS patients’ ability to process emotional feedback in the
GDT, since the GDT is not designed to obtain such a
measure precisely. Nevertheless, it is conceivable that ven-
tricular enlargement would also covary with reward-related
aspects of the GDT. Disturbances in communication be-
tween striatal and prefrontal brain regions, especially
dorsolateral prefrontal cortex, underlie deficits in decision-
making under explicit risk [26,29]. Indeed, in Muhlert
et al. [27] grey matter atrophy in the caudate and grey mat-
ter changes assessed via diffusion MRI (diffusion
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regions covaried with CGT-based decision-making speed
in MS patients. Relationships between structural brain
changes and other cognitive functions (especially process-
ing speed) covarying with the CGT were not assessed in
Muhlert et al. Therefore, it would be interesting to test
whether similar networks of brain regions are involved in
decision-making without a time restriction, such as in the
GDT. In general, emotional/reward-related elements of
decision-making [18] still play a role even in decisions
under explicit risk. That is, in addition to the cognitive/ex-
ecutive ability for making advantageous choices based on
the use of information about the winning/losing odds,
each trial in the GDT is also followed by reward or pun-
ishment feedback. The contribution of MS-related brain
changes to the proper use of feedback in decision situa-
tions should be explored further, using additional tasks
like the IGT, more contemporary neuroimaging tech-
niques and larger cohorts.
Strengths and limitations
The strengths of this study include the use of a decision-
making task that does not rely on speeded responses,
given that general slowing in speeded functions is prom-
inent in MS [3]. Furthermore, using a mediation model
we could uncover that processing speed deficits, al-
though showing a bivariate correlation with decision-
making, were rendered insignificant when taking central
atrophic brain changes into account. Understanding ven-
tricular enlargement measures as indices for disease
severity/progression, both processing speed deficits and
decision-making deficits may develop independently
from each other in the course of MS. Thus, our results
complement and extend the existing small body of lit-
erature on decision-making in MS by suggesting to
explore contributions of MS-related brain changes to as-
pects of decision-making that are separable from pro-
cessing speed deficits.
Among the limitations, it should be noted that the re-
sults of this study are preliminary based on the small sam-
ple size, especially with regard to our analyses in subgroup
samples. We intended the splitting of our RR-MS sub-
group to reflect the variability of cognitive impairment in
general, and decision-making deficits in particular across
the range of disability in MS. Since the correlation be-
tween GDT performance and EDSS scores achieves the
same outcome, one could alternatively avoid splitting the
RR subgroup and treat EDSS (or MSSS) solely parametric-
ally, possible only in larger samples. A more targeted in-
clusion of ‘benign’ MS patients, better-matched in
demographic background, would also be helpful to clarify
the exact characteristics of MS patients with intact GDT
performance. Evidently, acquiring standardized, high-
resolution MR allowing regional and whole-brain volumeassessment would be more precise than relying on retro-
spective sampling of rather heterogeneous 2-D MRIs.
Additional MS-related brain changes (e.g., lesion load) or
whole-brain atrophy measures (e.g., brain-parenchymal
fraction) would also be of interest to explore in addition
to the ventricular width measures. Such could address
questions surrounding different types and regional specifi-
city (if any) of MS-related brain pathologies to decision-
making in the GDT.
Furthermore, the MS patients were currently taking
a number of medications with potential influences on
cognitive functions. The sample size precluded any
further analyses based on current medication status,
but in larger cohorts, medication status should be
considered as a potentially important covariate. How-
ever, we would like to point out that despite the
current medications for symptom management and
mood, self-report questionnaires with regard to psycho-
logical problems did not point to major psychiatric co-
morbidities in our group (see Additional file 1). Finally,
patients were not currently experiencing relapses and
were not treated with corticosteroids. Historical infor-
mation about past relapse rates and preceding treat-
ment with corticosteroids was unfortunately not
available at the time of ascertainment of participants
and such has to be taken as a caveat.
Conclusions
Decision-making under explicit risk, as measured with the
GDT, was impaired in MS patients as a function of disabil-
ity severity. GDT performance was correlated with pro-
cessing speed in MS patients, even though the GDT is an
untimed decision-making task. However, both slowed pro-
cessing speed and GDT deficits were independently ex-
plained by the degree of central atrophy. These results
imply that MS-related atrophic brain changes may con-
tribute to decision-making deficits in the GDT irrespective
of their involvement in general processing speed deficits.
Individuals with MS are confronted with complex health-
related decisions concerning diagnostic and treatment
interventions that require proper handling such that a
compromised ability to oversee consequences of one’s de-
cisions could have wide-ranging effects. Our results may
imply that providing additional support (e.g., additional
time to make a decision) in those types of decision situa-
tions, especially for individuals in more advanced stages of
the disease, could be beneficial.
Additional files
Additional file 1: Psychosocial and symptom questionnaire scores
of MS patients compared to published norms/cut-off scores.
Additional file 2: Details of the T2-weighted axial 2-D MRIs used for
the ventricular width measures.
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axial magnetic resonance image. A: Frontal Horn Width (FHW); B:
Intercaudate Distance (ICD); C: Transverse Width (TW; used as denominator
for the Frontal Horn Ratio (FHR = FHW/TW), Intercaudate Ratio (ICR = ICR/TW)
and Third Ventricle Ratio (TVR = TVW/TW); D: Third Ventricle Width (TVW).
Additional file 4: Comparisons of ventricular width measures by
scan site and scanner model (31 MS patients and 20 non-MS control
patients). Data are means (standard deviations) or medians (ranges).
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